Withanolide B

Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects . In Vitro Withanolide B (1-100 nM; 3-5 days) significantly increases the expression of COL1A1 and RUNX2 genes and proteins in hBMSCs. Withanolide B (1-100 nM; 11 or 3 days) increases the formation of extracellular matrix calcium deposits and increased the activity of alkaline phosphatase (ALP). Withanolide B (1-100 nM; 3-5 days) increases the protein expressions of p-ERK and active β-catenin of hBMSCs. Withanolide B (10-100 μM; 48 h) reverses the Aβ42 aggregation-induced toxicy in SK-N-SH cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Human bone mesenchymal stem cells Concentration: 1, 10, 100 nM Incubation Time: 3, 5 days Result: Significantly increased the expression of COL1A1 and RUNX2. In Vivo Withanolide B (10 mg/kg; topical administration) promotes bone healing in a rat tibial defect model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (8 weeks, 200 g) with tibial defect Dosage: 10 mg/kg Administration: Injected in situ at the bone defect site at different time points (0, 3, 5, 7, and 9 days) Result: Increased the trabecular number, trabecular thickness and the thickness of the cortical bone. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet